Search results for "compatibility"

showing 10 items of 859 documents

Amide additives in polyolefins and imperfections in blown films

1985

Blow moldingMaterials scienceOleamideInfraredDiffusionGeneral EngineeringCompatibility (geochemistry)Polyethylenechemistry.chemical_compoundchemistryChemical engineeringAmidePolymer chemistryGeneral Materials ScienceJournal of Polymer Science: Polymer Letters Edition
researchProduct

Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers.

2006

AbstractTherapy of chronic respiratory diseases often involves inhalation therapy with nebulizers. Patients often attempt to shorten the time consuming administration procedure by mixing drug solutions/suspensions for simultaneous inhalation. This article considers the issue of physico-chemical compatibility of admixtures of drug solutions/suspensions in nebulizers.A search of databases, prescribing information and primary literature was conducted to locate literature concerning the physico-chemical compatibility of inhalation solutions/suspensions. This was supplemented by telephone interviews.Admixtures of albuterol with ipratropium and/or cromolyn, of albuterol and budesonide, or tobramy…

BudesonideDrugPulmonary and Respiratory MedicineRespiratory TherapyCystic Fibrosismedia_common.quotation_subjectReviewCompatibilityBenzalkonium chlorideAdministration InhalationCromolyn SodiummedicineDeoxyribonuclease IHumansAlbuterolPediatrics Perinatology and Child HealthAnti-Asthmatic AgentsBudesonideFenoterolmedia_commonExpectorantsInhalationbusiness.industryColistinIpratropiumNebulizers and VaporizersNebulizerAsthmaAcetylcysteineAnti-Bacterial AgentsBronchodilator AgentsNebulizerInhalation solutionsAnesthesiaPediatrics Perinatology and Child HealthIpratropiumColistinTobramycinDrug Therapy Combinationbusinessmedicine.drugJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
researchProduct

Defective expression of CD95 (FAS/APO-1) molecule suggests apoptosis impairment of T and B cells in HLA-B8, DR3-positive individuals.

1997

Activation-induced apoptosis is one of the primary control mechanisms for the negative selection of an immune response, leading to maintenance of immune homeostasis and selective T cell deletion. The interaction between the surface molecule Fas and its ligand (FasL) has been proposed as a primary mechanism initiating T cell apoptosis. The T cell receptor modulates the expression and function of these molecules. Defects in the Fas/FasL apoptosis pathway have been shown to result in autoimmune disease in humans and in murine models. Because subjects carrying the HLA-B8, DR3 haplotype show a number of immune dysfunctions, including membrano-proliferative glomerulonephritis, systemic lupus eryt…

CD3 ComplexT cellCD8 AntigensT-LymphocytesImmunologyAntigens CD19Lipopolysaccharide ReceptorsApoptosisBiologyFas ligandHLA-B8 AntigenImmune systemHLA-DR3 AntigenmedicineImmunology and AllergyCytotoxic T cellHumansfas ReceptorAutoimmune diseaseB-LymphocytesHistocompatibility TestingT-cell receptorGeneral Medicinemedicine.diseaseFas receptorFlow Cytometrymedicine.anatomical_structureApoptosisImmunologyCD4 AntigensCancer researchHuman immunology
researchProduct

Catumaxomab: a bispecific trifunctional antibody.

2009

The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells. The trifunctional approach thus leads to unrestricted but specific killing of epithelial tumor cells by major histocompatibility complex without the need for preactivation or external costimulation. The tumor-associated antigen EpCAM is strongly expressed in carcinomas of various origins including colon, rectum, ovarian, gastric, esophagus, lung, pancreas, breast and head and neck. Expressio…

CD3CatumaxomabAntineoplastic AgentsMajor histocompatibility complexchemistry.chemical_compoundAntigenAntigens NeoplasmNeoplasmsAntibodies BispecificMedicineAnimalsHumansPharmacology (medical)PharmacologybiologyBispecific monoclonal antibodybusiness.industryDrug Administration RoutesModels ImmunologicalEpithelial cell adhesion moleculeGeneral MedicineTrifunctional antibodychemistrybiology.proteinCancer researchAntibodyDrug Screening Assays Antitumorbusinessmedicine.drugDrugs of today (Barcelona, Spain : 1998)
researchProduct

Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient …

2001

Abstract Recombinant immunoreceptors with specificity for the carcinoembryonic Ag (CEA) can redirect grafted T cells to a MHC/Ag-independent antitumor response. To analyze receptor-mediated cellular activation in the context of CD28 costimulation, we generated: 1) CEA+ colorectal tumor cells that express simultaneously B7-1 and B7-2, and 2) CEA-specific immunoreceptors that harbor intracellularly the signaling moities either of CD28 (BW431/26-scFv-Fc-CD28), CD3ζ (BW431/26-scFv-Fc-CD3ζ), or FcεRIγ (BW431/26-scFv-Fc-γ). By retroviral gene transfer, we grafted activated T cells from the peripheral blood with these immunoreceptors. T cells that express the FcεRIγ or CD3ζ signaling receptor lyse…

CD4-Positive T-LymphocytesCD3 ComplexT cellCD3T-LymphocytesImmunologyEpitopes T-Lymphocytechemical and pharmacologic phenomenaBiologyCD8-Positive T-LymphocytesMajor histocompatibility complexLymphocyte ActivationTransfectionEpitopeAntigenCD28 AntigensAntigens NeoplasmmedicineTumor Cells CulturedImmunology and AllergyHumansReceptors ImmunologicReceptorReceptors IgGCD28hemic and immune systemsMolecular biologyCoculture TechniquesRecombinant ProteinsCell biologyCarcinoembryonic Antigenmedicine.anatomical_structurebiology.proteinB7-1 AntigenInterleukin-2CD8Signal TransductionJournal of immunology (Baltimore, Md. : 1950)
researchProduct

MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.

2003

The ability to activate CD4 T cells is restricted to antigen-presenting cells that express major histocompatibility complex (MHC) class II molecules. Parenchymal cells normally do not express MHC class II molecules; however, in clinical hepatitis, viral or autoimmune, hepatocytes often exhibit aberrant MHC class II expression. It is not known whether MHC class II-expressing hepatocytes can function as antigen-presenting cells, but it has been suggested that aberrant MHC class II expression by parenchymal cells may cause autoimmune disease. Therefore, we generated transgenic mice that specifically overexpress class II transactivator molecules in hepatocytes. Hepatocytes from these mice exhib…

CD4-Positive T-LymphocytesCD74Antigen presentationCD1Antigen-Presenting CellsGene ExpressionMice Inbred StrainsMice TransgenicLymphocyte ActivationHepatitisMiceMHC class ICytotoxic T cellAnimalsMHC class IIHepatologybiologyAntigen processingHistocompatibility Antigens Class IINuclear ProteinsMHC restrictionCell biologyImmunologybiology.proteinHepatocytesTrans-ActivatorsHepatology (Baltimore, Md.)
researchProduct

MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4

2015

A body of experimental evidence suggests that T cells mediate neuroprotection following CNS injury; however, the antigen specificity of these T cells and how they mediate neuroprotection are unknown. Here, we have provided evidence that T cell-mediated neuroprotection after CNS injury can occur independently of major histocompatibility class II (MHCII) signaling to T cell receptors (TCRs). Using two murine models of CNS injury, we determined that damage-associated molecular mediators that originate from injured CNS tissue induce a population of neuroprotective, IL-4-producing T cells in an antigen-independent fashion. Compared with wild-type mice, IL-4-deficient animals had decreased functi…

CD4-Positive T-LymphocytesCancer ResearchMAP Kinase Signaling SystemPopulationReceptors Antigen T-CellInflammationBiologyNeuroprotectionMiceAntigenClinical investigationAnimalsMedicineExtracellular Signal-Regulated MAP KinaseseducationReceptorInterleukin 4Mice Knockouteducation.field_of_studybusiness.industryT-cell receptorHistocompatibility Antigens Class IINeurodegenerative DiseasesGeneral MedicineAxonsCell biologyBrain InjuriesMyeloid Differentiation Factor 88Immunologybiology.proteinInterleukin-4medicine.symptomFunction and Dysfunction of the Nervous SystemCorrigendumbusinessProto-Oncogene Proteins c-aktResearch ArticleNeurotrophinJournal of Clinical Investigation
researchProduct

CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib–associated renal carcinoma antigens with ubiquitous or…

2004

AbstractAllogeneic hematopoietic stem cell transplantation can induce considerable tumor remissions in metastatic renal-cell carcinoma (RCC) patients. The precise effector mechanisms mediating these graft-versus-tumor reactions are unknown. We studied RCC-directed CD8+ T-cell responses in blood lymphocytes of healthy individuals matched with established RCC cell lines for HLA-class I. In 21 of 22 allogeneic mixed lymphocyte/tumor-cell cultures (MLTCs), RCC-reactive cytotoxic T-lymphocytes (CTLs) were readily obtained. From MLTCs, 121 CD8+ CTL clones with memory phenotype were isolated. Their anti–RCC reactivity was restricted by multiple classical HLA-Ia molecules, in particular by HLA-A2, …

CD4-Positive T-LymphocytesCytotoxicity ImmunologicGenotypemedicine.medical_treatmentMolecular Sequence DataImmunologyCell SeparationHuman leukocyte antigenHematopoietic stem cell transplantationCross ReactionsBiologyurologic and male genital diseasesBiochemistryEpitheliumCell therapyEpitopesAntigenAntigens NeoplasmmedicineHumansTransplantation HomologousCytotoxic T cellAmino Acid SequenceCarcinoma Renal CellHistocompatibility Antigens Class ICell BiologyHematologyImmunotherapyFlow CytometryHematopoietic Stem CellsTissue DonorsCTL*HealthSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationColonic NeoplasmsImmunologyMitogen-Activated Protein KinasesPeptidesCD8T-Lymphocytes CytotoxicBlood
researchProduct

Analysis of parathyroid graft rejection suggests alloantigen-specific production of nitric oxide by iNOS-positive intragraft macrophages

2009

Abstract Background During acute rejection of organ or tissue allografts T cells and macrophages are dominant infiltrating cells. CD4-positive T cells are important for the induction of allograft rejection and macrophages are important effector cells mediating cytotoxicity via production of nitric oxide (NO) by the inducible NO-synthase (iNOS). In the present study we analysed whether the destruction of primarily nonvascularised parathyroid allografts is also mediated by iNOS-positive macrophages. Methods Hypocalcaemic Lewis rats received parathyroid isografts (from Lewis donors) and allografts (from Wistar Furth donors), respectively, under the kidney capsule. Levels of serum calcium above…

CD4-Positive T-LymphocytesGraft RejectionMaleImmunologyThyroid GlandNitric Oxide Synthase Type IIRats Inbred WFInflammationCell CommunicationLymphocyte ActivationMajor histocompatibility complexNitric oxidechemistry.chemical_compoundAntigenCell MovementHistocompatibility AntigensmedicineAnimalsTransplantation HomologousImmunology and AllergyCytotoxic T cellMacrophageTransplantationbiologyChemistryMacrophage ActivationAntigens DifferentiationPeptide FragmentsRatsEnzyme ActivationTransplantationMononuclear cell infiltrationGene Expression RegulationRats Inbred LewImmunologyDisease ProgressionMacrophages Peritonealbiology.proteinCalciumImmunizationmedicine.symptomTransplant Immunology
researchProduct

Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.

2006

AbstractIn HLA-incompatible hematopoietic stem cell transplantation, alloreactive donor T cells recognizing recipient mismatch HLA cause severe graft-versus-host disease (GVHD). Strategies allowing the selective depletion of alloreactive T cells as well as the enhancement of graft-versus-malignancy immunity would be beneficial. We generated donor CD8 T-cell lines in vitro using allogeneic recipient cells mismatched at a single HLA class I allele or haplotype as stimulators. Recipient cells were obtained from acute myeloid leukemias, renal-cell carcinomas, and CD40L-induced B lymphoblasts. Resulting alloreactive T cells were activated by incubating day 21 T-cell cultures with HLA-mismatch tr…

CD4-Positive T-LymphocytesHerpesvirus 4 HumanIsoantigensT cellImmunologyCD40 LigandCytomegalovirusGraft vs Host DiseaseHuman leukocyte antigenBiologyCD8-Positive T-LymphocytesIn Vitro TechniquesLymphocyte ActivationTransfectionBiochemistryImmunotherapy AdoptiveLymphocyte DepletionTumor Necrosis Factor Receptor Superfamily Member 9AntigenHLA AntigensT-Lymphocyte SubsetsmedicineCytotoxic T cellHumansCarcinoma Renal CellCells CulturedSkinB-LymphocytesImmunomagnetic SeparationLymphoblastCD137Cell BiologyHematologyT lymphocyteFibroblastsCytotoxicity Tests ImmunologicKidney Neoplasmsmedicine.anatomical_structureLeukemia MyeloidHistocompatibilityImmunologyK562 CellsCD8Blood
researchProduct